CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect

  • Authors:
    • Hao‑Yu Xu
    • Nan Li
    • Nan Yao
    • Xiao‑Feng Xu
    • He‑Xi Wang
    • Xue‑Yang Liu
    • Yao Zhang
  • View Affiliations

  • Published online on: June 20, 2019     https://doi.org/10.3892/or.2019.7208
  • Pages: 866-879
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A satisfactory cure rate for renal cell carcinoma (RCC) is difficult to achieve through traditional immunotherapy. RCC has a relatively high spontaneous regression rate due to tumor immune escape. However, tumor‑derived exosomes (TEXs), which effectively carry tumor‑associated antigens (TAAs) and trigger stronger antigen‑specific tumor immunity against autologous tumors than against other tumors, have been widely viewed as attractive potential vaccines for tumor treatment, although improvements are needed. Therefore, in our study, we determined whether RenCa cell‑derived exosome (RDE)‑stimulated CD8+ T cells exert a stronger specific cytotoxic effect on autologous tumor cells than on other types of tumor cells through the Fas ligand (FasL)/Fas signaling pathway, and whether the combination of RDE‑stimulated CD8+ T cells with GM‑CSF and IL‑12 enhances the anticancer effect. The results showed that RDEs were isolated, as expected, and promoted an increased percentage of CD8+/CD4+ T cells. RDE‑stimulated CD8+ T cells also more effectively facilitated cytotoxicity against RenCa cells when combined with GM‑CSF and IL‑12 in vitro. Furthermore, immunization with RDEs restrained the growth of RenCa tumors in mouse models, and facilitated the stimulation of a stronger specific cytotoxic CD8+ T cell response via the FasL/Fas signaling pathway in vitro. However, these results were observed less frequently for other types of tumor cells after treatment with RDEs, suggesting that RDEs depend on their antigen specificity to trigger antitumor immune responses. These findings revealed that RDE‑stimulated CD8+ T cells combined with GM‑CSF and IL‑12 can more effectively exert a stronger cytotoxic effect than RDEs alone and that RDEs can induce immunization more effectively against renal cortical adenocarcinoma than against other types of cancer. Therefore, according to our study, exosomes are promising potential vaccines, and the combination of exosome‑stimulated CD8+ T cells with GM‑CSF and IL‑12 may be a novel strategy for the treatment of RCC.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC; European association of urology guideline group, : EAU guidelines on renal cell carcinoma: The 2010 update. Eur Urol. 58:398–406. 2010. View Article : Google Scholar : PubMed/NCBI

3 

Colombo M, Raposo G and Théry C: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 30:255–289. 2014. View Article : Google Scholar : PubMed/NCBI

4 

Sundararajan V, Sarkar FH and Ramasamy TS: Correction to: The versatile role of exosomes in cancer progression: Diagnostic and therapeutic implications. Cell Oncol (Dordr). 41:223–252. 2018. View Article : Google Scholar : PubMed/NCBI

5 

Gu X, Erb U, Büchler MW and Zöller M: Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice. Int J Cancer. 136:E74–E84. 2015. View Article : Google Scholar : PubMed/NCBI

6 

Stenqvist AC, Nagaeva O, Baranov V and Mincheva-Nilsson L: Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus. J Immunol. 191:5515–5523. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, et al: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 560:382–386. 2018. View Article : Google Scholar : PubMed/NCBI

8 

Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ and Whiteside TL: Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol. 183:3720–3730. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G and Rivoltini L: Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 66:9290–9298. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Huang F, Wan J, Hao S, Deng X, Chen L and Ma L: TGF-β1-silenced leukemia cell-derived exosomes target dendritic cells to induce potent anti-leukemic immunity in a mouse model. Cancer Immunol Immunother. 66:1321–1331. 2017. View Article : Google Scholar : PubMed/NCBI

11 

Huang F, Wan J, Hu W and Hao S: Enhancement of anti-leukemia immunity by leukemia-derived exosomes via downregulation of TGF-β1 expression. Cell Physiol Biochem. 44:240–254. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, et al: Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 120:457–471. 2010.PubMed/NCBI

13 

Yang MQ, Du Q, Varley PR, Goswami J, Liang Z, Wang R, Li H, Stolz DB and Geller DA: Interferon regulatory factor 1 priming of tumour-derived exosomes enhances the antitumour immune response. Br J Cancer. 118:62–71. 2018. View Article : Google Scholar : PubMed/NCBI

14 

Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O and Geuze HJ: Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem. 273:20121–20127. 1998. View Article : Google Scholar : PubMed/NCBI

15 

Xie Y, Bai O, Zhang H, Yuan J, Zong S, Chibbar R, Slattery K, Qureshi M, Wei Y, Deng Y and Xiang J: Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70. J Cell Mol Med. 14:2655–2666. 2010. View Article : Google Scholar : PubMed/NCBI

16 

Bu N, Wu H, Sun B, Zhang G, Zhan S, Zhang R and Zhou L: Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma. J Neurooncol. 104:659–667. 2011. View Article : Google Scholar : PubMed/NCBI

17 

Hao S, Bai O, Yuan J, Qureshi M and Xiang J: Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol. 3:205–211. 2006.PubMed/NCBI

18 

Yao Y, Chen L, Wei W, Deng X, Ma L and Hao S: Tumor cell-derived exosome-targeted dendritic cells stimulate stronger CD8+ CTL responses and antitumor immunities. Biochem Biophys Res Commun. 436:60–65. 2013. View Article : Google Scholar : PubMed/NCBI

19 

Kreuwel HT, Morgan DJ, Krahl T, Ko A, Sarvetnick N and Sherman LA: Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus. J Immunol. 163:4335–4341. 1999.PubMed/NCBI

20 

Sayers TJ, Brooks AD, Lee JK, Fenton RG, Komschlies KL, Wigginton JM, Winkler-Pickett R and Wiltrout RH: Molecular mechanisms of immune-mediated lysis of murine renal cancer: Differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. J Immunol. 161:3957–3965. 1998.PubMed/NCBI

21 

Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH and Sayers TJ: Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol. 168:3484–3492. 2002. View Article : Google Scholar : PubMed/NCBI

22 

Zhang Y, Luo CL, He BC, Zhang JM, Cheng G and Wu XH: Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: A novel vaccine for renal cell carcinoma. Int J Oncol. 36:133–140. 2010.PubMed/NCBI

23 

Wang J, De Veirman K, Faict S, Frassanito MA, Ribatti D, Vacca A and Menu E: Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression. J Pathol. 239:162–173. 2016. View Article : Google Scholar : PubMed/NCBI

24 

Baldan V, Griffiths R, Hawkins RE and Gilham DE: Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma. Br J Cancer. 112:1510–1518. 2015. View Article : Google Scholar : PubMed/NCBI

25 

Yuan Y, Zhang Y, Zhao S, Chen J, Yang J, Wang T, Zou H, Wang Y, Gu J, Liu X, et al: Cadmium-induced apoptosis in neuronal cells is mediated by Fas/FasL-mediated mitochondrial apoptotic signaling pathway. Sci Rep. 8:88372018. View Article : Google Scholar : PubMed/NCBI

26 

Junker K, Heinzelmann J, Beckham C, Ochiya T and Jenster G: Extracellular vesicles and their role in urologic malignancies. Eur Urol. 70:323–331. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Graner MW, Schnell S and Olin MR: Tumor-derived exosomes, microRNAs, and cancer immune suppression. Semin Immunopathol. 40:505–515. 2018. View Article : Google Scholar : PubMed/NCBI

28 

Barros FM, Carneiro F, Machado JC and Melo SA: Exosomes and immune response in cancer: Friends or foes? Front Immunol. 9:7302018. View Article : Google Scholar : PubMed/NCBI

29 

Ludwig S, Floros T, Theodoraki MN, Hong CS, Jackson EK, Lang S and Whiteside TL: Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer. Clin Cancer Res. 23:4843–4854. 2017. View Article : Google Scholar : PubMed/NCBI

30 

Troyer RM, Ruby CE, Goodall CP, Yang L, Maier CS, Albarqi HA, Brady JV, Bathke K, Taratula O, Mourich D and Bracha S: Exosomes from osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells. Exp Cell Res. 358:369–376. 2017. View Article : Google Scholar : PubMed/NCBI

31 

Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL and Boyiadzis M: Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica. 96:1302–1309. 2011. View Article : Google Scholar : PubMed/NCBI

32 

Kunigelis KE and Graner MW: The dichotomy of tumor exosomes (TEX) in cancer immunity: Is it all in the ConTEXt? Vaccines (Basel). 3:1019–1051. 2015. View Article : Google Scholar : PubMed/NCBI

33 

Mignot G, Roux S, Thery C, Ségura E and Zitvogel L: Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med. 10:376–388. 2006. View Article : Google Scholar : PubMed/NCBI

34 

Rao Q, Zuo B, Lu Z, Gao X, You A, Wu C, Du Z and Yin H: Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro. Hepatology. 64:456–472. 2016. View Article : Google Scholar : PubMed/NCBI

35 

Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, Hao X, Joyce JA, Hanley HH, Riordan NH, Koropatnick J, et al: Exosomes as a tumor immune escape mechanism: Possible therapeutic implications. J Transl Med. 6:372008. View Article : Google Scholar : PubMed/NCBI

36 

Vignaux F, Vivier E, Malissen B, Depraetere V, Nagata S and Golstein P: TCR/CD3 coupling to Fas-based cytotoxicity. J Exp Med. 181:781–786. 1995. View Article : Google Scholar : PubMed/NCBI

37 

Lenardo M, Chan KM, Hornung F, McFarland H, Siegel R, Wang J and Zheng L: Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol. 17:221–253. 1999. View Article : Google Scholar : PubMed/NCBI

38 

Kang YT, Kim YJ, Bu J, Cho YH, Han SW and Moon BI: High-purity capture and release of circulating exosomes using an exosome-specific dual-patterned immunofiltration (ExoDIF) device. Nanoscale. 9:13495–13505. 2017. View Article : Google Scholar : PubMed/NCBI

39 

Dai S, Wei D, Wu Z, Zhou X, Wei X and Huang H: Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther. 16:782–790. 2008. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

August 2019
Volume 42 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xu, H., Li, N., Yao, N., Xu, X., Wang, H., Liu, X., & Zhang, Y. (2019). CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect. Oncology Reports, 42, 866-879. https://doi.org/10.3892/or.2019.7208
MLA
Xu, H., Li, N., Yao, N., Xu, X., Wang, H., Liu, X., Zhang, Y."CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect". Oncology Reports 42.2 (2019): 866-879.
Chicago
Xu, H., Li, N., Yao, N., Xu, X., Wang, H., Liu, X., Zhang, Y."CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect". Oncology Reports 42, no. 2 (2019): 866-879. https://doi.org/10.3892/or.2019.7208